Christopher A. Simon
Net Worth
Last updated:
What is Christopher A. Simon net worth?
The estimated net worth of Mr. Christopher A. Simon is at least $37,797,227 as of 29 Jun 2023. He owns shares worth $11,421,411 as insider, has earned $8,105,816 from insider trading and has received compensation worth at least $18,270,000 in Haemonetics Corporation.
What is the salary of Christopher A. Simon?
Mr. Christopher A. Simon salary is $2,030,000 per year as Chief Executive Officer, Pres & Director in Haemonetics Corporation.
How old is Christopher A. Simon?
Mr. Christopher A. Simon is 61 years old, born in 1964.
What stocks does Christopher A. Simon currently own?
As insider, Mr. Christopher A. Simon owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Haemonetics Corporation (HAE) | Chief Executive Officer, Pres & Director | 213,724 | $53.44 | $11,421,411 |
What does Haemonetics Corporation do?
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Christopher A. Simon insider trading
Haemonetics Corporation
Mr. Christopher A. Simon has made 21 insider trades between 2016-2023, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 196,746 units of HAE stock on 29 Jun 2023. As of 29 Jun 2023 he still owns at least 213,724 units of HAE stock.
Haemonetics key executives
Haemonetics Corporation executives and other stock owners filed with the SEC:
- Mr. Christopher A. Simon (61) Chief Executive Officer, Pres & Director
- Mr. Josep Lluis Llorens (63) Senior Vice President of Global Manufacturing & Supply Chain
- Mr. William P. Burke (57) Chief Financial Officer & Executive Vice President
- Ms. Anila Lingamneni (58) Executive Vice President & Chief Technology Officer
- Ms. Michelle L. Basil (53) Executive Vice President, Gen. Counsel & Sec.